Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast

NCT00003857 is registered in ClinicalTrials.gov with Radiation Therapy Oncology Group as lead sponsor.

NCT NCT00003857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast
Lead sponsor
Radiation Therapy Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
December 31, 1999
Completion date
May 20, 2022
Enrollment
636 (actual)
Sites
369

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer